BIOMAT Database Logo BIOMAT Database Logo

Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. 2010

R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
Brno Epilepsy Centre, First Department of Neurology, St. Anne's Teaching Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic. robert.kuba@fnusa.cz

OBJECTIVE To assess the long-term efficacy and tolerability of levetiracetam in routine clinical practice. METHODS We retrospectively analysed 218 patients, mostly adults, presenting mostly with localisation-related epilepsy, treated with levetiracetam as adjunctive therapy or monotherapy for up to 36 months. The primary points evaluated were: long-term retention rate, reasons for discontinuing levetiracetam and the percentage of seizure-free patients. RESULTS The retention rate at 6, 12, 24 and 36 months following the commencement of levetiracetam treatment was 91.7, 75.2, 60.1 and 53.7% respectively. Sixty-seven (30.7%) patients discontinued levetiracetam treatment. During the clinical audit evaluation period, surgical resection or implantation of VNS was performed in 31 (14.3%) patients. In 53 of the 67 patients (79.1%), the treatment was discontinued due to lack of efficacy; in 14 patients (20.9%) treatment was discontinued due to adverse events. In total, 24 of 218 patients (11.0%) were seizure-free for 36 months. CONCLUSIONS Levetiracetam is an effective and well-tolerated option for long-term treatment of epilepsy in adults.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010889 Piracetam A compound suggested to be both a nootropic and a neuroprotective agent. 2-Pyrrolidone-N-Acetamide,Avigilen,Axonyl,Cerebroforte,Cerepar N,Ciclofalina,Cuxabrain,Dinagen,Gabacet,Geram,Memo-Puren,Nootrop,Nootropil,Nootropyl,Normabraïn,Piracebral,Piracetam AbZ,Piracetam-RPh,Piracetrop,Pirazetam,Pyracetam,Pyramem,Sinapsan,UCB-6215,Memo Puren,Piracetam RPh,UCB 6215,UCB6215
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077287 Levetiracetam A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent. Etiracetam,Etiracetam, (R)-,Etiracetam, R-isomer,Etiracetam, S-isomer,Keppra,UCB 6474,UCB-6474,Ucb L059,Ucb L060,Ucb-L059,Ucb-L060,alpha-ethyl-2-oxo-1-Pyrrolidineacetamide,Etiracetam, R isomer,Etiracetam, S isomer,R-isomer Etiracetam,S-isomer Etiracetam,UCB6474,UcbL060,alpha ethyl 2 oxo 1 Pyrrolidineacetamide
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
April 2003, Seizure,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
[Effectiveness and safety of long-term levetiracetam treatment in patients with refractory epilepsy].
July 2015, No to hattatsu = Brain and development,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
Long-term continuation of levetiracetam in patients with refractory epilepsy.
June 2001, Neurology,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
Long-term follow-up of patients with benign partial epilepsy in infancy.
January 2006, Epilepsia,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
Treatment and long-term follow-up of cats with suspected primary epilepsy.
April 2013, Journal of feline medicine and surgery,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study.
March 2005, Seizure,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
[Long-term follow-up of absence epilepsy].
January 1989, No to hattatsu = Brain and development,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
[Follow-up study on levetiracetam monotherapy in children with epilepsy].
December 2008, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy.
March 2004, Epilepsy research,
R Kuba, and I Novotná, and M Brázdil, and J Kocvarová, and I Tyrlíková, and J Mastík, and I Rektor
Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up.
August 2021, Epilepsy & behavior : E&B,
Copied contents to your clipboard!